<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993379</url>
  </required_header>
  <id_info>
    <org_study_id>CTMX-M-072-002</org_study_id>
    <nct_id>NCT03993379</nct_id>
  </id_info>
  <brief_title>PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors</brief_title>
  <official_title>A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytomX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytomX Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in
      adult patients with solid tumor based upon overall response rate by Response Evaluation
      Criteria in Solid Tumors (RECIST)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's Decision
  </why_stopped>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">May 21, 2020</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate by RECIST v 1,1</measure>
    <time_frame>1 year</time_frame>
    <description>ORR by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients experiencing Treatment Related Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Safety and Tolerability of CX-072 in Combination Therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The numbers of patients experiencing anti-tumor activity by irRECIST</measure>
    <time_frame>2 years</time_frame>
    <description>ORR by irRECIST</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Unresectable or Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>CX-072 in combination with anti-cancer therapy-front line</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>histologically or cytologically confirmed solid tumor who have received no prior treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-072 in combination with ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-072 in combination with anti-cancer therapy-Progressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-072 in combination with anti-cancer therapy-Neoadjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neo-adjuvant study in subjects with histologically confirmed solid tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-072</intervention_name>
    <description>CX-072 in combination with ipilimumab</description>
    <arm_group_label>CX-072 in combination with anti-cancer therapy-Neoadjuvant</arm_group_label>
    <arm_group_label>CX-072 in combination with anti-cancer therapy-Progressed</arm_group_label>
    <arm_group_label>CX-072 in combination with anti-cancer therapy-front line</arm_group_label>
    <arm_group_label>CX-072 in combination with ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>CX-072 in combination with ipilimumab</description>
    <arm_group_label>CX-072 in combination with ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age

          2. Measurable disease as defined by RECIST v1.1

          3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

          4. Agree to provide tumor tissue and blood samples for biomarker assessment

        Exclusion Criteria:

          1. Treatment with cytotoxic chemotherapy, biologic agents, radiation, immunotherapy, or
             any investigational agent within 28 days prior to the first dose of study treatment.

          2. Prior therapy with a chimeric antigen receptor T cell-containing regimen

          3. History of active autoimmune disease(s) including but not limited to inflammatory
             bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis,
             systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune
             neuropathies, type 1 insulin-dependent diabetes mellitus

          4. History of myocarditis regardless of the cause

          5. History of intolerance to prior checkpoint inhibitor therapy defined as the need to
             discontinue treatment due to an irAE

          6. History of any syndrome or medical condition that required treatment with systemic
             steroids (≥10 mg daily prednisone equivalents) or immunosuppressive medications.

          7. History of severe allergic or anaphylactic reactions to human mAb therapy or known
             hypersensitivity to any Probody therapeutic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Lu, MD</last_name>
    <role>Study Director</role>
    <affiliation>CytomX Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Cancer Care</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYC Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Dwight and March Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Institute for Research and Innovation</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Private Hospital</name>
      <address>
        <city>Sunshine Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballarat Oncology and Haematology Services</name>
      <address>
        <city>Wendouree</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet, Hospital Duran I Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona. Servicio Oncologia Medica</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START- Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combination</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>Cancer</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>PD-L1</keyword>
  <keyword>CTLA-4</keyword>
  <keyword>PROCLAIM</keyword>
  <keyword>PROCLAIM-CX-072</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

